GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NuVasive Inc (NAS:NUVA) » Definitions » Long-Term Capital Lease Obligation

NuVasive (NuVasive) Long-Term Capital Lease Obligation : $100 Mil (As of Jun. 2023)


View and export this data going back to 2004. Start your Free Trial

What is NuVasive Long-Term Capital Lease Obligation?

NuVasive's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was $100 Mil.

NuVasive's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 ($104 Mil) to Mar. 2023 ($102 Mil) and declined from Mar. 2023 ($102 Mil) to Jun. 2023 ($100 Mil).

NuVasive's annual Long-Term Capital Lease Obligation declined from Dec. 2020 ($112 Mil) to Dec. 2021 ($112 Mil) and declined from Dec. 2021 ($112 Mil) to Dec. 2022 ($104 Mil).


NuVasive Long-Term Capital Lease Obligation Historical Data

The historical data trend for NuVasive's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuVasive Long-Term Capital Lease Obligation Chart

NuVasive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 73.15 111.63 111.59 103.81

NuVasive Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 106.69 104.73 103.81 101.61 99.82

NuVasive  (NAS:NUVA) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

NuVasive Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of NuVasive's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


NuVasive (NuVasive) Business Description

Traded in Other Exchanges
N/A
Address
12101 Airport Way, Broomfield, CO, USA, 92121
NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures.
Executives
Michael Farrington officer: SVP, People and Culture 7475 LUSK BLVD., SAN DIEGO CA 92121
Marc W. Rosenbaum officer: Chief Accounting Officer 7475 LUSK BLVD., SAN DIEGO CA 92121
James Christopher Barry director, officer: Chief Executive Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Andrew C. Morton officer: SVP, CHRO 10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Amy Belt Raimundo director ONE KAISER PLAZA, 22ND FLOOR, OAKLAND CA 94612
Lucas Vitale officer: Chief Human Resources Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Massimo Calafiore officer: EVP, Global Business Units 7475 LUSK BLVD., SAN DIEGO CA 92121
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Brent J. Boucher officer: EVP, Global Commercial 14 PLAZA DRIVE, LATHAM NY 12110
Matthew Link officer: Exec. VP U.S. Sales 7475 LUSK BLVD, SAN DIEGO CA 92121
Matthew K Harbaugh officer: EVP and CFO 675 MCDONNELL BLVD., HAZELWOOD MO 63042
Dale A. Wolf officer: SVP, Global Operations 7475 LUSK BLVD., SAN DIEGO CA 92121
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Mcclintock officer: President, U.S. Commercial 7475 LUSK BLVD, SAN DIEGO CA 92121